Premium
Evidence‐based recommendations for the use of WBC‐reduced cellular blood components
Author(s) -
Ratko Thomas A.,
Cummings Joseph P.,
Oberman Harold A.,
Crookston Kendall P.,
DeChristopher Phillip J.,
Eastlund D. Ted,
Godwin John E.,
Sacher Ronald A.,
Yawn David H.,
Matuszewski Karl A.
Publication year - 2001
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.2001.41101310.x
Subject(s) - transfusion medicine , medicine , medical laboratory , family medicine , health science , center (category theory) , blood transfusion , gerontology , emergency medicine , medical education , pathology , chemistry , crystallography
In the United States, approximately 12 million to 14 million units of blood are donated annually.1 These units typically are fractionated into some 20 million blood components, mainly RBCs, platelets, and FFP.2 Alternatively, plasma, RBCs, and platelets may be obtained by apheresis. On average, 3 million to 4 million patients receive Evidence-based recommendations for the use of WBC-reduced cellular blood components